Navigation Links
Isis Pharmaceuticals Updates Its Positive Phase 2 Data for ISIS,301012 in Familial Hypercholesterolemia Patients

* Treatment with ISIS 301012 produced at least 45% additional reduction in patients' LDL-cholesterol when added to maximally-tolerated lipid-lowering therapies

CARLSBAD, Calif., May 17, 2007 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals, Inc. announced updated results from its ongoing Phase 2 clinical trial of ISIS 301012 in patients with homozygous familial hypercholesterolemia (HoFH), initial results of which were presented in March at the of Cardiology Annual Scientific Session (ACC) in New Orleans. The three HoFH patients dosed with 300 mg/week of ISIS 301012 for twelve weeks have now completed treatment. With ISIS 301012, the patients achieved 45%, 50% and 51% additional reductions in LDL-cholesterol beyond that achieved with maximally-tolerated lipid-lowering therapy, with similar reductions in apoB of 45%, 43% and 54%. ISIS 301012 continued to be well tolerated in the study.

"The magnitude of LDL-cholesterol response in these three HoFH patients has surpassed anything I have seen in the last 30 years, including with statins," stated Evan Stein, M.D., Ph.D., Director, Metabolic and Atherosclerosis Research Center, Cincinnati, Ohio, lead investigator in the study. "It offers for the first time the potential for good, life-long control of LDL without expensive and invasive therapies such as apheresis, liver transplantation and other heroic measures we have tried over the years."

ISIS 301012 has been granted orphan drug status for the treatment of homozygous FH, one of the most severe forms of hypercholesterolemia and one that is highly resistant to treatment. Patients with this genetic condition typically suffer heart attacks at an early age. Isis plans to begin registration-directed studies for FH in 2007.

ISIS 301012 in Homozygous Familial Hypercholesterolemia

The data presented are part of a single-arm, open-label, dose-escalation study. Because the study was designed princip
'"/>




Page: 1 2 3 4 5

Related medicine technology :

1. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
2. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
4. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
5. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
6. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
7. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
8. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
9. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
10. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
11. Arisaph Pharmaceuticals Announces Results of its Potent Smart DPP-4 Inhibitor, ARI-2243, at the ADA
Post Your Comments:
(Date:4/1/2015)... April 1, 2015   Advocates for Responsible Care ... health care professionals, patient advocates and human rights ... which will go live at 9:00 a.m. today. ... in Reach is a new campaign to limit rising ... families. Led by Advocates for Responsible Care, in partnership with ...
(Date:4/1/2015)... NEW YORK , April 1, 2015   ... management solutions, will showcase advances in monitored care that ... the upcoming HIMSS 2015 Conference. The conference ... Chicago , from April 12 through 16. In ... at their respective booths, AMC Health will share innovations ...
(Date:4/1/2015)... VANCOUVER, British Columbia and MENLO ... DelMar Pharmaceuticals, Inc. (OTCQX: DMPI) ("DelMar" and ... industry veteran, Erich Mohr , Ph.D., R.Psych., to ... Dr. Mohr has close to two decades of ... scientific officer, chief executive officer and board member, including ...
Breaking Medicine Technology:'Rx in Reach' Campaign Launches in Georgia 2'Rx in Reach' Campaign Launches in Georgia 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 2AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 3AMC Health Demonstrates Advances in Monitored Care at HIMSS 2015 4DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 2DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 3DelMar Pharmaceuticals Appoints Biopharmaceutical Industry Veteran, Erich Mohr, Ph.D., R.Psych., to the Board of Directors 4
... Oct. 12 Thousands of people with disabilities, their families, ... attend Abilities Expo on Friday, October 15, through Sunday, October ... free and show hours will be Friday 11 am to ... 11 am to 4 pm. Abilities Expo has ...
... that a new market research report is available ... Pharmaceutical Ingredients (APIs) Market to 2015 - Rise ... Growth http://www.reportlinker.com/p0312072/Active-Pharmaceutical-Ingredients-APIs-Market-to-2015---Rise-in-the-Generic-and-Biotech-Sector-will-Sustain-Growth.html ... to 2015 - Rise in the Generic and ...
Cached Medicine Technology:People With Disabilities Experience Their Possibilities at Abilities Expo in Atlanta, Georgia 2People With Disabilities Experience Their Possibilities at Abilities Expo in Atlanta, Georgia 3Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 2Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 3Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 4Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 5Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 6Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 7Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 8Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 9Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 10Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 11Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 12Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 13Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 14Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 15Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 16Reportlinker Adds Active Pharmaceutical Ingredients (APIs) Market to 2015 - Rise in the Generic and Biotech Sector will Sustain Growth 17
(Date:4/1/2015)... BioPlus Specialty Pharmacy (BioPlus), ... released a new app to keep health care providers ... hepatitis C virus (HCV) infection. This ‘HCV Treatment Path’ ... the American Association for the Study of Liver Diseases ... direct-acting oral medications to treat HCV have been approved ...
(Date:4/1/2015)... Dr. Daniel C. Stewart will be ... the benefits of the LANAP® treatment over traditional ... People who live in Howard County, and surrounding areas ... visit Dr. Stewart, a Maryland dentist, for a minimally ... protocol, which is a laser gum surgery procedure, Dr. ...
(Date:4/1/2015)... 2015 OSF Saint Paul Medical Center, ... , was welcomed into the Ministry April 1, 2015, ... Paul E. Showalter, vicar general of the Catholic Diocese ... culminated a nearly year-long transition process for the former ... Speakers for the morning ceremony included Sister Judith Ann ...
(Date:4/1/2015)... 01, 2015 Aging2.0 , the ... announces the launch of the Aging2.0 Alliance ... stakeholders and technology companies. The announcement was made today ... and Business Strategies Forum in San Diego, CA. ... Alliance program is now open for additional members. “This ...
(Date:4/1/2015)... Dr. Rod J. Rohrich , ... of the Department of Plastic Surgery at UT Southwestern ... reports of blindness resulting from the use of ... published their study, along with ideas for treatment and ... "We began to see increasing reports of blindness as ...
Breaking Medicine News(10 mins):Health News:BioPlus Specialty Pharmacy Releases ‘HCV Treatment Path’ App for Hepatitis C Providers 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 2Health News:Dr. Daniel C. Stewart Offers Columbia Area Residents an Informational Seminar in April About Less Invasive Gum Disease Treatment Now Available at Smile Savers Dentistry 3Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 2Health News:Mendota Community Hospital Now OSF Saint Paul Medical Center 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 2Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 3Health News:Aging2.0 Announces Launch of New Membership Community, Aging2.0 Alliance 4Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 2Health News:Dr. Rod J. Rohrich and Colleagues Study Rare Occurrences of Blindness Caused by Use of Facial Fillers 3
... (Pink,Sheets: MEDQ) today announced that its board of directors ... stock. The dividend will,be paid on August 4, 2008 ... on July 25, 2008., Newcastle Partners, L.P., along ... shareholder derivative lawsuit in the Superior Court of,New Jersey, ...
... BETHESDA, MD --JULY 15, 2008 The Carnegie Corporation ... international scientific outreach program through the American Society for ... technologies to emerging research institutions in sub-Saharan Africa. The ... month in Morogoro, Tanzania, when ASCB members present a ...
... predicts up to 2.2 million additional cases in U.S. by ... and increased dehydration linked to global warming will boost kidney ... new research suggests. , In the United States in particular, ... stone disease among residents of southern states -- the so-called ...
... Group ... Benefits -, PHILADELPHIA, July ... ) today announced it,will move to a new and expanded Dental panel ... 1, 2008. The,Lincoln DentalConnect(SM) plan, provides access to more than 52,000 unique,dentists ...
... clot forms in heart and travels to the brain, heparin ... -- The widely prescribed blood-thinning drug heparin is associated with ... suffered a cardioembolic stroke, new research shows. , But ... harmful effects in the same group of patients. , This ...
... 2008 Closing coal-fired power plants can have a ... according to a study released by the Columbia Center ... School of Public Health. The study allowed researchers ... of children born in Tongliang, a city in China,s ...
Cached Medicine News:Health News:MedQuist Announces Declaration of $2.75 per share Dividend on Common Stock 2Health News:Carnegie Corporation funds ASCB course on parasites for African scientists 2Health News:Global Warming Linked to Heightened Kidney Stone Risk 2Health News:Global Warming Linked to Heightened Kidney Stone Risk 3Health News:Lincoln Financial Group Announces New Dental Panel of Providers 2Health News:Lincoln Financial Group Announces New Dental Panel of Providers 3Health News:Warfarin Safer Than Heparin for Some Strokes 2Health News:Closing coal-burning power plant in China and improved cognitive development in children 2Health News:Closing coal-burning power plant in China and improved cognitive development in children 3
Athroscopic leg holder system....
The 300 watt Xenon light source will provide intense illumination necessary for demanding, advanced endoscopic procedures....
The 15 and 18 Sony Flat Screen Monitors with articulating arm can be used in conjunction with existing surgical monitors or as replacements....
Standard arthroscope with telescope (4 mm) for large joints....
Medicine Products: